SGLT2i therapy demonstrated early clinical benefits in cardiorenal health and inflammation in older adults with hypertension and pre-heart failure. Findings published in Cardiology evaluated the effect of dapagliflozin on cardiac remodeling and kidney function.
Eighty-eight patients were enrolled from August 2022 to August 2024 and randomized to dapagliflozin or conventional therapy. N-terminal pro-brain natriuretic peptide (NT-proBNP), troponin I (TnI), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), procalcitonin (PCT), left ventricular end-diastolic volume (LVEDV), left atrial volume index (LAVI), and estimated glomerular filtration rate (eGFR) were assessed at baseline and after three months.
Baseline measures were similar between groups. After treatment, IL-6, hsCRP, and LAVI improved significantly in the dapagliflozin group compared with controls (p < 0.05), with improved eGFR also observed. NT-proBNP, TnI, and LVEDV remained stable.
These findings indicate that SGLT2i therapy may support early myocardial remodeling, reduce inflammatory burden, and maintain renal function in this high-risk population.
